Close Menu

NEW YORK (GenomeWeb) – Menarini-Silicon Biosystems said today that it has signed an agreement to purchase all the assets and relevant business related to the Cellsearch circulating tumor cell (CTC) system from Janssen Diagnostics for an undisclosed amount.

Cellsearch is used to help manage patients with metastatic breast, prostate, and colorectal cancers. It is the only US Food and Drug Administration-cleared CTC test, and has been approved by the China FDA for use in monitoring breast cancer patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.